(MYCR) Mycronic publ - Ratings and Ratios
Mask Writers, Measuring Machines, SMT Equipment, Dispensing Equipment, Testing
MYCR EPS (Earnings per Share)
MYCR Revenue
Description: MYCR Mycronic publ
Mycronic AB (publ) is a Swedish company that develops, manufactures, and sells production equipment for the electronics industry globally, operating through four segments: Pattern Generators, High Flex, High Volume, and Global Technologies. The companys products cater to various industries, including aerospace, consumer, defense, medical, communication, computers, and industrial electronics.
The companys diverse product portfolio includes mask writers and measuring machines for advanced photomasks, surface mount technology (SMT) and inspection equipment, dispensing and conformal coating equipment for circuit boards, and die bonding services for microelectronics and optoelectronic applications. This broad range of offerings positions Mycronic as a key player in the electronics manufacturing equipment market.
To evaluate Mycronics performance, we can consider key performance indicators (KPIs) such as revenue growth, order intake, and gross margin. The companys ability to maintain a strong order backlog and deliver products to customers on time is crucial. Additionally, Mycronics research and development (R&D) expenses as a percentage of sales can indicate its commitment to innovation and staying ahead in the competitive electronics manufacturing equipment market.
From a financial perspective, Mycronics market capitalization of 42.7 billion SEK and a return on equity (RoE) of 29.94% suggest a significant presence in the market and a decent return for shareholders. The price-to-earnings (P/E) ratio of 21.68 indicates that the stock is trading at a reasonable valuation relative to its earnings. To further analyze the stocks potential, we can examine its dividend yield, payout ratio, and cash flow generation.
Considering the companys global presence, diversified product portfolio, and financial performance, Mycronic AB (publ) appears to be a significant player in the electronics manufacturing equipment industry. Further analysis of its financial statements, industry trends, and competitive landscape can provide a more comprehensive understanding of the companys prospects and investment potential.
MYCR Stock Overview
| Market Cap in USD | 4,370m |
| Sub-Industry | Electronic Equipment & Instruments |
| IPO / Inception |
MYCR Stock Ratings
| Growth Rating | 57.2% |
| Fundamental | 87.5% |
| Dividend Rating | 38.3% |
| Return 12m vs S&P 500 | -2.34% |
| Analyst Rating | - |
MYCR Dividends
| Dividend Yield 12m | 1.33% |
| Yield on Cost 5y | 3.01% |
| Annual Growth 5y | -5.59% |
| Payout Consistency | 89.6% |
| Payout Ratio | 18.6% |
MYCR Growth Ratios
| Growth Correlation 3m | 82.5% |
| Growth Correlation 12m | 34.1% |
| Growth Correlation 5y | 72.7% |
| CAGR 5y | 18.34% |
| CAGR/Max DD 5y | 0.33 |
| Sharpe Ratio 12m | -0.12 |
| Alpha | -1.44 |
| Beta | 0.994 |
| Volatility | 36.28% |
| Current Volume | 74.4k |
| Average Volume 20d | 92.8k |
| Stop Loss | 205.6 (-3%) |
| Signal | -2.62 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (1.97b TTM) > 0 and > 6% of Revenue (6% = 482.8m TTM) |
| FCFTA 0.14 (>2.0%) and ΔFCFTA -5.82pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 39.29% (prev 44.78%; Δ -5.48pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.14 (>3.0%) and CFO 1.42b <= Net Income 1.97b (YES >=105%, WARN >=100%) |
| Net Debt (-1.80b) to EBITDA (1.96b) ratio: -0.92 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.16 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (195.6m) change vs 12m ago 100.4% (target <= -2.0% for YES) |
| Gross Margin 54.37% (prev 53.18%; Δ 1.19pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 82.81% (prev 71.12%; Δ 11.70pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 120.6 (EBITDA TTM 1.96b / Interest Expense TTM 15.0m) >= 6 (WARN >= 3) |
Altman Z'' 6.25
| (A) 0.31 = (Total Current Assets 5.89b - Total Current Liabilities 2.73b) / Total Assets 10.35b |
| (B) 0.46 = Retained Earnings (Balance) 4.71b / Total Assets 10.35b |
| (C) 0.19 = EBIT TTM 1.81b / Avg Total Assets 9.72b |
| (D) 1.44 = Book Value of Equity 5.14b / Total Liabilities 3.57b |
| Total Rating: 6.25 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 87.48
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 3.55% = 1.78 |
| 3. FCF Margin 17.66% = 4.41 |
| 4. Debt/Equity 0.03 = 2.50 |
| 5. Debt/Ebitda 0.10 = 2.49 |
| 6. ROIC - WACC 12.75% = 12.50 |
| 7. RoE 29.94% = 2.49 |
| 8. Rev. Trend 84.67% = 4.23 |
| 9. Rev. CAGR 21.33% = 2.50 |
| 10. EPS Trend 63.30% = 1.58 |
| 11. EPS CAGR 14.83% = 1.48 |
What is the price of MYCR shares?
Over the past week, the price has changed by -1.58%, over one month by -0.70%, over three months by +12.08% and over the past year by +14.24%.
Is Mycronic publ a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MYCR is around 212.41 SEK . This means that MYCR is currently overvalued and has a potential downside of 0.17%.
Is MYCR a buy, sell or hold?
What are the forecasts/targets for the MYCR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 238 | 12.2% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 239.3 | 12.9% |
MYCR Fundamental Data Overview
Market Cap SEK = 41.62b (41.62b SEK * 1.0 SEK.SEK)
CCE Cash And Equivalents = 1.80b SEK (last quarter)
P/E Trailing = 21.093
P/S = 5.173
P/B = 6.18
P/EG = 0.21
Beta = 0.961
Revenue TTM = 8.05b SEK
EBIT TTM = 1.81b SEK
EBITDA TTM = 1.96b SEK
Long Term Debt = 127.0m SEK (from longTermDebtTotal, last quarter)
Short Term Debt = 70.0m SEK (from shortTermDebt, last quarter)
Debt = 197.0m SEK (Calculated: Short Term 70.0m + Long Term 127.0m)
Net Debt = -1.80b SEK (from netDebt column, last quarter)
Enterprise Value = 40.02b SEK (41.62b + Debt 197.0m - CCE 1.80b)
Interest Coverage Ratio = 120.6 (Ebit TTM 1.81b / Interest Expense TTM 15.0m)
FCF Yield = 3.55% (FCF TTM 1.42b / Enterprise Value 40.02b)
FCF Margin = 17.66% (FCF TTM 1.42b / Revenue TTM 8.05b)
Net Margin = 24.52% (Net Income TTM 1.97b / Revenue TTM 8.05b)
Gross Margin = 54.37% ((Revenue TTM 8.05b - Cost of Revenue TTM 3.67b) / Revenue TTM)
Tobins Q-Ratio = 7.79 (Enterprise Value 40.02b / Book Value Of Equity 5.14b)
Interest Expense / Debt = 7.61% (Interest Expense 15.0m / Debt 197.0m)
Taxrate = 19.00% (from yearly Income Tax Expense: 396.0m / 2.08b)
NOPAT = 1.47b (EBIT 1.81b * (1 - 19.00%))
Current Ratio = 2.16 (Total Current Assets 5.89b / Total Current Liabilities 2.73b)
Debt / Equity = 0.03 (Debt 197.0m / last Quarter total Stockholder Equity 6.74b)
Debt / EBITDA = 0.10 (Net Debt -1.80b / EBITDA 1.96b)
Debt / FCF = 0.14 (Debt 197.0m / FCF TTM 1.42b)
Total Stockholder Equity = 6.59b (last 4 quarters mean)
RoA = 19.06% (Net Income 1.97b, Total Assets 10.35b )
RoE = 29.94% (Net Income TTM 1.97b / Total Stockholder Equity 6.59b)
RoCE = 26.93% (Ebit 1.81b / (Equity 6.59b + L.T.Debt 127.0m))
RoIC = 22.42% (NOPAT 1.47b / Invested Capital 6.54b)
WACC = 9.66% (E(41.62b)/V(41.82b) * Re(9.68%)) + (D(197.0m)/V(41.82b) * Rd(7.61%) * (1-Tc(0.19)))
Shares Correlation 5-Years: 70.0 | Cagr: 18.97%
Discount Rate = 9.68% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 76.31% ; FCFE base≈1.56b ; Y1≈1.93b ; Y5≈3.29b
Fair Price DCF = 214.6 (DCF Value 41.88b / Shares Outstanding 195.2m; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: 84.67 | Revenue CAGR: 21.33%
Rev Growth-of-Growth: 4.12
EPS Correlation: 63.30 | EPS CAGR: 14.83%
EPS Growth-of-Growth: -45.63